(HealthDay News) — Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online in JAMA Psychiatry.

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, warranting further clinical investigation.

FRIDAY, Nov. 22, 2024 (HealthDay News) -- Semaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD), according to a study published ...

A clinical trial shows that people who were considered by medical researchers to report signs of alcohol use disorder drank significantly less after taking semaglutide for two months, compared to ...

A new study showed that semaglutide (known under the brand name Ozempic) may help with alcohol use disorder.

A study of 48 people with signs of moderate alcohol-use disorder found that those taking low doses of semaglutide – the generic name of Ozempic – for nine weeks saw significantly greater ...

New research finds that semaglutide, the active ingredient in GLP-1 drugs like Ozempic and Wegovy, may significantly reduce alcohol cravings in people with alcohol use disorder (AUD) and type 2 ...

GLP-1 medications that have helped people lose weight may also help people drink less alcohol, according to new government-funded research.